Literature DB >> 26201805

Changing etiology of liver failure in 3,916 patients from northern China: a 10-year survey.

Shaoli You1, Yihui Rong2, Bing Zhu3, Aimin Zhang4, Hong Zang5, Hongling Liu6, Dongze Li7, Zhihong Wan8, Shaojie Xin9.   

Abstract

PURPOSE: To investigate the etiological characteristics of patients with liver failure in the past 10 years.
METHODS: Clinical and investigational data in hospitalized patients with liver failure admitted from 2002 to 2011 were retrospectively analyzed. Standard definitions and criteria were used to assess disease etiology.
RESULTS: Of these 3,916 patients, 3,429 (87.6 %) had acute-on-chronic liver failure (ACLF), 114 (2.9 %) acute liver failure (ALF), and 373 (9.5 %) subacute liver failure. Viral infection was the most common cause of liver failure in the 3,295 patients (84.1 %). Hepatitis of unknown etiology was deemed responsible for 371 cases of liver failure (9.5 %). Drug-induced liver injury, alcoholic hepatitis, and autoimmune hepatitis led to 120 cases (3.1 %), 109 cases (2.8 %), and 19 cases (0.5 %), respectively. The most common cause of ACLF was HBV infection (87.3 %), while the main causes of acute and subacute liver failure were hepatitis of unknown etiology (39.4 %), viral infection (36.6 %), and drug-induced liver injury (19.3 %). Our data showed that the incidence of liver failure caused by HBV gradually decreased from 86.5 % in 2002 to 69.2 % in 2011. However, the incidence of hepatitis of unknown etiology, drug-induced liver injury, and alcoholic hepatitis was increased.
CONCLUSIONS: HBV infection is the main cause of liver failure in China. However, the incidence of HBV-related liver failure has gradually decreased in the past 10 years. Hepatitis of unknown etiology has replaced HBV infection as the most common apparent cause of acute liver failure.

Entities:  

Keywords:  Etiology; Liver failure; Liver injury; Prognosis

Year:  2013        PMID: 26201805     DOI: 10.1007/s12072-013-9424-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  27 in total

1.  Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition.

Authors:  Fan Jian-gao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2010-03

2.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

Review 3.  Changing etiologies and outcomes of acute liver failure: A perspective from Japan.

Authors:  Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

4.  Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries.

Authors:  Bjørn Brandsaeter; Krister Höckerstedt; Styrbjörn Friman; Bo-Göran Ericzon; Preben Kirkegaard; Helena Isoniemi; Michael Olausson; Ulrika Broome; Lars Schmidt; Aksel Foss; Kristian Bjøro
Journal:  Liver Transpl       Date:  2002-11       Impact factor: 5.799

5.  Epidemiological and clinical features of hepatitis B virus related liver failure in China.

Authors:  Chen Liu; Yu-Ming Wang; Ke Fan
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

6.  Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Kun Huang; Jin-Hua Hu; Hui-Fen Wang; Wei-Ping He; Jing Chen; Xue-Zhang Duan; Ai-Min Zhang; Xiao-Yan Liu
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

Review 7.  Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.

Authors:  Zhuanbo Luo; Lanjuan Li; Bing Ruan
Journal:  Int J Infect Dis       Date:  2011-12-17       Impact factor: 3.623

8.  Drug-induced liver disease: an 8-year study of patients from one gastroenterological department.

Authors:  Yi Ping Wang; Bin Shi; Yue Xiang Chen; Jing Xu; Cai Feng Jiang; Wei Fen Xie
Journal:  J Dig Dis       Date:  2009-08       Impact factor: 2.325

9.  Fulminant hepatic failure: a Portuguese experience.

Authors:  Miguel Areia; José Manuel Romãozinho; Manuela Ferreira; Pedro Amaro; Maximino Correia Leitão
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-08       Impact factor: 2.566

10.  Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure.

Authors:  Johannes Hadem; Penelope Stiefel; Matthias J Bahr; Hans L Tillmann; Kinan Rifai; Jürgen Klempnauer; Heiner Wedemeyer; Michael P Manns; Andrea S Schneider
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03       Impact factor: 11.382

View more
  20 in total

1.  Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.

Authors:  Zhi-Hong Wan; Jian-Jun Wang; Shao-Li You; Hong-Ling Liu; Bing Zhu; Hong Zang; Chen Li; Jing Chen; Shao-Jie Xin
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Granulocyte Colony-Stimulating Factor Accelerates the Recovery of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure by Promoting M2-Like Transition of Monocytes.

Authors:  Jingjing Tong; Hongmin Wang; Xiang Xu; Zhihong Wan; Hongbin Fang; Jing Chen; Xiuying Mu; Zifeng Liu; Jing Chen; Haibin Su; Xiaoyan Liu; Chen Li; Xiaowen Huang; Jinhua Hu
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

3.  Single-Cell RNA Transcriptomics Reveals the State of Hepatic Lymphatic Endothelial Cells in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.

Authors:  Pengpeng Zhang; Hao Li; Chen Zhou; Kai Liu; Bo Peng; Xingguo She; Ke Cheng; Hong Liu; Yingzi Ming
Journal:  J Clin Med       Date:  2022-05-20       Impact factor: 4.964

4.  Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure.

Authors:  Bing Zhu; Shao-Li You; Zhi-Hong Wan; Hong-Ling Liu; Yi-Hui Rong; Hong Zang; Shao-Jie Xin
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

5.  Aberrant methylation of UBE2Q1 promoter is associated with poor prognosis of acute-on-chronic hepatitis B pre-liver failure.

Authors:  Na Hu; Xian-Ci Xie; Lin-Lin Liu; Wei-Dong Lai
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

6.  Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure.

Authors:  Zhihong Wan; Yichen Wu; Jing Yi; Shaoli You; Hongling Liu; Zhiqiang Sun; Bing Zhu; Hong Zang; Chen Li; Fangfang Liu; Dongze Li; Yuanli Mao; Shaojie Xin
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

7.  Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.

Authors:  Ke Wang; Zhe-Bin Wu; Yi-Nong Ye; Jing Liu; Geng-Lin Zhang; Yu-Jie Su; Hong-Liang He; Yu-Bao Zheng; Zhi-Liang Gao
Journal:  Hepat Mon       Date:  2014-07-14       Impact factor: 0.660

8.  Associations between hepatitis B virus basal core promoter/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis.

Authors:  Feishu Hu; Sheng Bi; Huadong Yan; Yu Shi; Jifang Sheng
Journal:  Virol J       Date:  2015-06-11       Impact factor: 4.099

9.  Association of Hepatitis B Virus Mutations of A1846T and C1913A/G With Acute-on-Chronic Liver Failure Development From Different Underlying Chronic Liver Diseases.

Authors:  Aimin Zhang; Zhihong Wan; Shaoli You; Hongling Liu; Bing Zhu; Jing Chen; Yihui Rong; Hong Zang; Chen Li; Huifen Wang; Shaojie Xin
Journal:  Hepat Mon       Date:  2013-09-01       Impact factor: 0.660

Review 10.  Hepatitis E: Update on Prevention and Control.

Authors:  Juliana Gil Melgaço; Noemi Rovaris Gardinali; Vinicius da Motta de Mello; Mariana Leal; Lia Laura Lewis-Ximenez; Marcelo Alves Pinto
Journal:  Biomed Res Int       Date:  2018-01-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.